 |
|
Decreased Inflammation and Improved Survival With Recombinant Human Activated Protein C Treatment in Experimental Acute Pancreatitis—Invited Response
Guido Alsfasser, MD;
Andrew L. Warshaw, MD;
Carlos Fernández-del Castillo, MD
Arch Surg. 2006;141:677.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In the 15 years since we first described our pancreatitis model,1 we have performed dozens of experimental studies related to its pathogenesis and treatment and have never before encountered an intervention with such a dramatic effect in the early phases of the disease. It is not only that we found a significantly improved 24-hour survival, but also that surviving rats (almost the entire treatment group) appeared remarkably healthier. We were surprised when evaluation of the pancreas showed no difference between controls and treated rats, and from there we assume the improvement related to less lung injury, which is the earliest and most common form of organ failure associated with pancreatitis. This hypothesis is backed by the almost complete normalization of myeloperoxidase concentration in lungs. Myeloperoxidase has been found by us and other investigators2-3 to correlate very closely with both . . . [Full Text of this Article]
AUTHOR INFORMATION
RELATED ARTICLES
Decreased Inflammation and Improved Survival With Recombinant Human Activated Protein C Treatment in Experimental Acute Pancreatitis
Guido Alsfasser, Andrew L. Warshaw, Sarah P. Thayer, Bozena Antoniu, Michael Laposata, Kent B. Lewandrowski, and Carlos Fernández-del Castillo
Arch Surg. 2006;141(7):670-676.
ABSTRACT
| FULL TEXT
Decreased Inflammation and Improved Survival With Recombinant Human Activated Protein C Treatment in Experimental Acute Pancreatitis—Invited Critique
Dana K. Andersen
Arch Surg. 2006;141(7):676.
EXTRACT
| FULL TEXT
|
